Drug intelligence / Profile preview

ABV-104

Development stage: Preclinical
Lead developer: AbVacc
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**ABV-104** is an investigational preclinical **monoclonal-antibody cocktail** being developed by AbVacc, in collaboration with Eliteimmune, as a non-antibiotic adjunctive immunotherapy for invasive *Staphylococcus aureus* infections. Publicly available program materials identify it as an anti-*S. aureus* antibody cocktail, but do not disclose the individual antibody components, epitopes, molecular targets, route, or formulation. ([abvacc.com](https://abvacc.com/antibody.html))

Beyond the preview

Go deeper on ABV-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABV-104.

Explore the full profile